Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up
Phase of Trial: Phase III
Latest Information Update: 27 Dec 2017
At a glance
- Drugs Ingenol disoxate (Primary)
- Indications Actinic keratosis
- Focus Registrational; Therapeutic Use
- Sponsors LEO Pharma
- 20 Dec 2017 Status changed from active, no longer recruiting to completed.
- 22 Mar 2017 Planned End Date changed from 1 Aug 2017 to 1 Oct 2017.
- 22 Mar 2017 Status changed from recruiting to active, no longer recruiting.